Amneal Acquires Kashiv BioSciences to Build Biosimilar Empire

Amneal Pharmaceuticals has completed its acquisition of Kashiv BioSciences, the company announced, establishing a fully integrated global platform that spans biosimilar research and development, manufacturing, and commercialization in a single unified operation.

The deal positions Amneal as a formidable force in the fast-growing biosimilars market, where demand for lower-cost alternatives to complex biologic drugs has surged as patents on blockbuster therapies continue to expire. By absorbing Kashiv's specialized capabilities, Amneal gains an internal pipeline and production infrastructure that many rivals must source externally.

Read more China's C919 Completes First International Flight in Duopoly Challenge →

Integrating R&D and manufacturing under one roof is widely viewed as a competitive advantage in biosimilars, where development timelines are long and regulatory scrutiny is intense. The combined entity is expected to accelerate Amneal's ability to bring biosimilar candidates from discovery through clinical testing and into the commercial marketplace without relying heavily on third-party partners.

The move signals Amneal's strategic bet that biosimilars will be a defining growth engine for generic and specialty pharmaceutical companies over the next decade, as health systems and payers worldwide push aggressively for cost-effective biologic alternatives. Analysts have noted that companies controlling the full value chain tend to capture meaningfully higher margins and move faster to market.

Continue reading at GlobalNewswire.